• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

FDA Guidance for COVID-19 Convalescent Plasma to Remain in Effect

March 22, 2023

During the public health emergency for COVID-19, the U.S. Food and Drug Administration (FDA) issued guidance for the use of convalescent plasma to treat COVID-19.  Recently, it has been recommended that COVID-19 convalescent plasma be provided to immunocompromised individuals who are at high risk of severe disease and death.  As monoclonal antibodies have become ineffective, the use of convalescent plasma has increased.  Now, as the public health emergency for COVID-19 is set to expire on May 11, 2023, some of the FDA guidance documents will concurrently expire.  The guidance, however, for COVID-19 convalescent plasma will remain in effect at least until November 7, 2023—180 days after the end of the public health emergency.  This will give the FDA additional time to finalize revised guidance for COVID-19 convalescent plasma.  Thus, clinicians may continue to treat hospitalized patients and patients who are immunocompromised with convalescent plasma and to enroll patients in randomized controlled trials.

References:

  1. FDA Regulatory Information.  Investigational COVID-19 Convalescent Plasma.  Guidance for Industry.  March 13, 2023.  
  2. Bloch EM, Focosi D, Shoham S, Senefeld J, Tobian AAR, et al. Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019 (COVID-19), Clinical Infectious Diseases, 2023;, ciad066

Filed Under

  • News
  • Policy and Guidelines

Recommended

  • Most Blood Donors Are Motivated by Altruism

  • Darbepoetin Alfa Reduces RBC Transfusions in Infants with HDFN Treated with Intrauterine Transfusions

  • Drone Delivery of Blood Products Faster in Rwanda and Reduces Wastage

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • RBCs with Reduced Deformability are Removed from Circulation

  • Array-based, comprehensive genotyping for erythroid, platelet, neutrophil and leukocyte antigens

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley